JP2022513721A5 - - Google Patents
Info
- Publication number
- JP2022513721A5 JP2022513721A5 JP2021531983A JP2021531983A JP2022513721A5 JP 2022513721 A5 JP2022513721 A5 JP 2022513721A5 JP 2021531983 A JP2021531983 A JP 2021531983A JP 2021531983 A JP2021531983 A JP 2021531983A JP 2022513721 A5 JP2022513721 A5 JP 2022513721A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- patient
- level
- composition
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024072811A JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776253P | 2018-12-06 | 2018-12-06 | |
| US62/776,253 | 2018-12-06 | ||
| US201962840431P | 2019-04-30 | 2019-04-30 | |
| US62/840,431 | 2019-04-30 | ||
| US201962842063P | 2019-05-02 | 2019-05-02 | |
| US62/842,063 | 2019-05-02 | ||
| PCT/US2019/064190 WO2020117772A1 (en) | 2018-12-06 | 2019-12-03 | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072811A Division JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513721A JP2022513721A (ja) | 2022-02-09 |
| JP2022513721A5 true JP2022513721A5 (https=) | 2022-12-08 |
Family
ID=68966114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531983A Withdrawn JP2022513721A (ja) | 2018-12-06 | 2019-12-03 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
| JP2024072811A Pending JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072811A Pending JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12429487B2 (https=) |
| EP (1) | EP3890752A1 (https=) |
| JP (2) | JP2022513721A (https=) |
| KR (1) | KR20210102294A (https=) |
| CN (1) | CN113365640A (https=) |
| BR (1) | BR112021010660A2 (https=) |
| CA (1) | CA3121749A1 (https=) |
| MA (1) | MA54383A (https=) |
| MX (1) | MX2021006548A (https=) |
| WO (1) | WO2020117772A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| CN114667597A (zh) | 2019-06-11 | 2022-06-24 | 库力索法荷兰有限公司 | 在分立部件的组装中用于位置误差补偿的材料 |
| WO2022091086A1 (en) * | 2020-10-26 | 2022-05-05 | Hadasit Medical Research Services And Development Ltd. | Mesenchymal stem cells and their culture |
| KR200498472Y1 (ko) | 2024-05-23 | 2024-10-24 | 김민경 | 경고 또는 안내 문구를 교체형으로 구성시킬 수 있는 배수용 그레이팅 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2221376B1 (en) | 2001-06-21 | 2012-11-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| EP3470072A1 (en) | 2005-06-23 | 2019-04-17 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing |
| WO2008127974A1 (en) | 2007-04-13 | 2008-10-23 | The Trustees Of Columbia University In The City Of New York | Stem cell-based culture system for drug development |
| HRP20250897T1 (hr) | 2009-05-02 | 2025-09-26 | Genzyme Corporation | Genska terapija za neurodegenerativne poremećaje |
| ES2699827T3 (es) | 2009-06-17 | 2019-02-13 | Biogen Ma Inc | Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| WO2013170068A2 (en) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| CN104968783B (zh) | 2012-10-15 | 2019-12-10 | Ionis制药公司 | 用于调节c9orf72表达的组合物 |
| CA2889499C (en) * | 2012-10-24 | 2019-09-10 | Daiichi Sankyo Company, Limited | Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis |
| WO2014110291A1 (en) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| US10221414B2 (en) | 2013-10-11 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| WO2015057727A1 (en) | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| CA2926341A1 (en) | 2013-10-14 | 2015-04-23 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of c9orf72 antisense transcript |
| EP3119888B1 (en) | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
| HUE050704T2 (hu) * | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| US10024870B2 (en) | 2014-04-02 | 2018-07-17 | Wisconsin Alumni Research Foundation | Therapeutic and diagnostic methods and compositions for neurodegenerative diseases |
| EP3797780B1 (en) | 2014-04-17 | 2022-09-14 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| SG10201902850TA (en) | 2014-09-30 | 2019-04-29 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
| RS60230B1 (sr) | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| AU2016381174A1 (en) | 2015-12-31 | 2018-05-31 | Ionis Pharmaceuticals, Inc. | Methods for reducing Ataxin-2 expression |
| US20190142856A1 (en) | 2016-04-13 | 2019-05-16 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
| WO2018218219A1 (en) | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| EA201992364A1 (ru) | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
| US12162952B2 (en) | 2018-04-27 | 2024-12-10 | Neurimmune Ag | Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody |
| WO2020061355A2 (en) | 2018-09-20 | 2020-03-26 | Biogen Ma Inc. | Serum neurofilament protein for guiding therapeutic intervention in multiple sclerosis |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| TWI906204B (zh) | 2018-12-14 | 2025-12-01 | 美商百健Ｍａ公司 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
| US20220128578A1 (en) | 2019-02-12 | 2022-04-28 | Biogen Ma Inc. | Biomarkers of progressive multifocal leukoencephalopathy |
-
2019
- 2019-12-03 US US17/299,660 patent/US12429487B2/en active Active
- 2019-12-03 KR KR1020217020744A patent/KR20210102294A/ko active Pending
- 2019-12-03 JP JP2021531983A patent/JP2022513721A/ja not_active Withdrawn
- 2019-12-03 MX MX2021006548A patent/MX2021006548A/es unknown
- 2019-12-03 CA CA3121749A patent/CA3121749A1/en active Pending
- 2019-12-03 CN CN201980080522.8A patent/CN113365640A/zh active Pending
- 2019-12-03 EP EP19824179.6A patent/EP3890752A1/en active Pending
- 2019-12-03 WO PCT/US2019/064190 patent/WO2020117772A1/en not_active Ceased
- 2019-12-03 BR BR112021010660-0A patent/BR112021010660A2/pt unknown
- 2019-12-03 MA MA054383A patent/MA54383A/fr unknown
-
2024
- 2024-04-26 JP JP2024072811A patent/JP2024096258A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513721A5 (https=) | ||
| Chen et al. | Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases | |
| JP2021035369A (ja) | 自己抗体関連疾患に対する使用のためのアプタマー | |
| BR112019017851A2 (pt) | método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo | |
| Zhou et al. | Diverse roles of macrophages in intraocular neovascular diseases: a review | |
| Won et al. | Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma | |
| US11214804B2 (en) | Aptamers for the treatment of sickle cell disease | |
| US11660306B2 (en) | Treatment of Rett syndrome | |
| JP2024518374A (ja) | トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法 | |
| Pidala et al. | Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial | |
| Barsotti et al. | One year in review 2017: idiopathic inflammatory myopathies | |
| JP2022540993A5 (https=) | ||
| Zhou et al. | Identification and clinical significance of tsRNAs and miRNAs in PBMCs of treatment-requiring retinopathy of prematurity | |
| JP7713489B2 (ja) | Ｂ因子阻害剤の使用方法 | |
| WO2024030909A1 (en) | Biomarkers of amino acid composition treatment response in long covid | |
| JP2024525515A (ja) | がんの予防用又は治療用の医薬組成物 | |
| JP2024511767A5 (https=) | ||
| Wang et al. | Myostatin silencing inhibits podocyte apoptosis in membranous nephropathy through Smad3/PKA/NOX4 signaling pathway | |
| CN107847564B (zh) | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 | |
| WO2023080157A1 (ja) | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）の治療又は予防剤、並びに、ｈａｍの治療有効性判定方法、活動性評価方法又は診断方法 | |
| You et al. | Silencing USP19 alleviates cigarette smoke extract-induced mitochondrial dysfunction in BEAS-2B cells by targeting FUNDC1 | |
| US20250312332A1 (en) | Treatment of muscle fibrosis | |
| Rob et al. | Efficacy and safety evaluation of different lebrikizumab dosages in atopic dermatitis patients over 16 to 24 weeks: a BIOREP registry analysis | |
| US20220144931A1 (en) | Methods of treatment of muscular dystrophies | |
| Guo et al. | Calcitriol ameliorates the progression of hepatic fibrosis through autophagy-related gene 16-like 1-mediated autophagy |